Is Stereotaxis Inc (STXS) overvalued? · rev $26.9M
Stereotaxis Inc (STXS) is a medical instruments & supplies company listed on AMEX.
This page asks whether Stereotaxis Inc (STXS) looks expensive on cached numbers — not a short thesis.
Latest reported STXS revenue for 2024-12-31 was $26.9M. Net income was -$24.0M. Revenue was up 0.5% from 2023-12-31 to 2024-12-31. STXS currently screens at market cap $174.0M.
STXS currently screens at market cap $174.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next STXS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the STXS stock page for the full model, not this heading.
Not investment advice.